Inflationary pressures and higher oil prices, exacerbated by Middle East conflict, could increase manufacturing and transportation costs for ANI Pharmaceuticals.

Broader economic uncertainty and potential global growth downgrades by institutions like the IMF may impact overall healthcare spending and investor sentiment towards pharmaceutical companies, though the sector is often considered defensive.

A strong U.S. labor market, indicated by job additions and low unemployment, could support domestic consumer spending and healthcare benefits, potentially driving demand for ANI Pharmaceuticals' products in the United States.